A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Biomarkers of MIN-102 (Leriglitazone)

Uwe Meya, Guillem Pina, Silvia Pascual, Marc Cerrada-Gimenez, Pilar Pizcueta, Marc Martinell, David Eckland, Jeroen v.d. Wetering de Rooij
Neurology Apr 2020, 94 (15 Supplement)

Evaluation of the pharmacokinetic parameters of leriglitazone in plasma and urine after single and multiple oral administration in healthy male volunteers. Evaluation of pro-inflammatory biomarkers in plasma and CSF after oral administration of leriglitazone in healthy male volunteers.